Skip to content

Study · Measured the body's own peptide · 1990

3 results

Neurophysins as markers of vasopressin and oxytocin release. A study in carcinoma of the lung.

Legros JJ, Geenen V, Carvelli T, Martens H, Andre M, Corhay JL, Radermecker M, Zangerle PF, Sassolas G, Gharib C

Hormone research1 Jan 1990Cited by 13 (Europe PMC)

PMID1966564 (opens in a new tab)DOI10.1159/000181815 (opens in a new tab)PepBankPUB-01966564
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with lung carcinoma, oxytocin-neurophysin (hNpII), a marker of oxytocin release, was increased in some oat cell and undifferentiated-cell carcinoma patients.

    In plain wordsIn people with lung cancer, a marker of the body's own oxytocin release was raised in some oat cell and undifferentiated tumours.

    Peptide
    Oxytocin
    Outcome
    IncreaseOxytocin-neurophysin (hNpII) level in oat cell and undifferentiated-cell carcinoma
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    hNpII was increased together with an increase in hNpI in 6 oat cell carcinoma patients; it was specifically increased without hNpI increment in 2 additional oat cell carcinoma patients and in 2 patients of the undifferentiated-cell carcinoma group
    1 context sentence
    Summary · context
    Vasopressin-neurophysin (hNpI), oxytocin-neurophysin (hNpII) and blood osmolality were assayed before any treatment in basal conditions in 35 patients suffering from lung carcinoma (20 oat cell, 6 undifferentiated and 9 well-differentiated epidermoid cell carcinomas).

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with lung carcinoma, oxytocin-neurophysin (hNpII) was normal in the majority of undifferentiated and in all differentiated epidermoid-cell carcinoma patients.

    In plain wordsIn people with lung cancer, the marker of the body's own oxytocin release was normal in most undifferentiated and all differentiated epidermoid tumours.

    Peptide
    Oxytocin
    Outcome
    No significant changeOxytocin-neurophysin (hNpII) level in epidermoid carcinoma
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    hNpI and hNpII were normal in the majority of undifferentiated and all of the differentiated epidermoid-cell carcinoma group.
    1 context sentence
    Summary · context
    Vasopressin-neurophysin (hNpI), oxytocin-neurophysin (hNpII) and blood osmolality were assayed before any treatment in basal conditions in 35 patients suffering from lung carcinoma (20 oat cell, 6 undifferentiated and 9 well-differentiated epidermoid cell carcinomas).

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In patients with lung carcinoma, combined measurement of hNpI, hNpII and blood osmolality detected abnormalities in 17 of 20 oat cell and 4 of 9 undifferentiated-cell carcinoma patients, and in none of the differentiated epidermoid-cell patients.

    In plain wordsIn lung cancer, markers of the body's own oxytocin release, tested together, found abnormalities in most oat cell tumours and no epidermoid tumours.

    Peptide
    Oxytocin
    Outcome
    Not applicableDetection of abnormalities by combined hNpI, hNpII and osmolality measurement
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    our results show that simultaneous measurements of hNpI, hNpII, and blood osmolality could detect abnormalities in 17 out of 20 oat cell carcinoma patients, in 4 of the 9 undifferentiated-cell carcinoma patients, but in none of the differentiated epidermoid-cell carcinoma patients
    1 context sentence
    Summary · context
    Vasopressin-neurophysin (hNpI), oxytocin-neurophysin (hNpII) and blood osmolality were assayed before any treatment in basal conditions in 35 patients suffering from lung carcinoma (20 oat cell, 6 undifferentiated and 9 well-differentiated epidermoid cell carcinomas).

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:53 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.